Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit
Home Articles Vol 34,2025 No.9 Detail

Guide on Methodological Standards in Pharmacoepidemiology (2nd edition) and their series interpretation (9): research report standards and results visualization

Published on Sep. 27, 2025Total Views: 37 times Total Downloads: 7 times Download Mobile

Author: CHENG Jingru 1, 2 CHEN Ruina 1, 2 LI Jiarui 1, 2 TANG Shaowen 1, 2 SUN Feng 3, 4, 5, 6, 7, 8 ZHAN Siyan 3, 4, 5, 9

Affiliation: 1. Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, China 2. Institute of Pharmacovigilance, Nanjing Medical University, Nanjing 211166, China 3. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China 4. Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China 5. Center for Post-Marketing Safety Evaluation of Drugs, Peking University Health Science Center, Beijing 100191, China 6. Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China 7. College of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830017, China 8. School of Medicine, Shihezi University, Shihezi 832000, Xinjiang Uygur Autonomous Region, China 9. Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing 100191, China

Keywords: Pharmacoepidemiology Methodology Guildelines Research report Visualization

DOI: 10.12173/j.issn.1005-0698.202508056

Reference: CHENG Jingru, CHEN Ruina, LI Jiarui, TANG Shaowen, SUN Feng, ZHAN Siyan. Guide on Methodological Standards in Pharmacoepidemiology in China (2nd edition) and their series interpretation (9): research report standards and results visualization[J]. Yaowu Liuxingbingxue Zazhi, 2025, 34(9): 1004-1016. DOI: 10.12173/j.issn.1005-0698.202508056.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Standardized research reporting is crucial for the translation of pharmacoepidemiology research findings, and visual reporting can significantly enhance the clarity, understandability, and transparency of research results. Based on the Guide on Methodological Standards in Pharmacoepidemiology (2nd edition), this article systematically explains the key points for writing each component of a research report (including title, abstract, introduction, research methods, research results, discussion and conclusions, acknowledgments, conflict of interest statement, and references). This article also summarizes recognized international and domestic standards for pharmacoepidemiology research reporting, providing a reference for researchers. Furthermore, real-world cases will be used to demonstrate common forms of visualized reports and their interpretation methods. Finally, it further explores strategies for communicating research results. This study aims to provide pharmacoepidemiology researchers with detailed guidance on visually presenting research results and writing high-quality research reports, thereby enhancing the integrity and impact of their research.

Full-text
Please download the PDF version to read the full text: download
References

1.Sabaté M, Montané E. Pharmacoepidemiology: an overview[J]. J Clin Med, 2023, 12(22): 7033. DOI: 10.3390/jcm122270D33.

2.Montastruc JL, Benevent J, Montastruc F, et al. What is pharmacoepidemiology? Definition, methods, interest and clinical applications[J]. Therapie, 2019, 74(2): 169-174. DOI: 10.1016/j.therap.2018.08.001.

3.Cooke CR. Facilitating existing success and continued growth at AnnalsATS through better study reporting[J]. Ann Am Thorac Soc, 2020, 17(5): 555-556. DOI: 10.1513/AnnalsATS.202003-210ED.

4.The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (revision 11) [R/OL]. (2023-07-13) [2025-07-18]. https://encepp.europa.eu/encepp-toolkit/methodological-guide_en.

5.Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practice (GPP)[J]. Pharmacoepidemiol Drug Saf, 2016, 25(1): 2-10. DOI: 10.1002/pds.3891.

6.U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry and FDA Staff Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data[S/OL]. (2013-05-14) [2025-07-18]. https://www.fda.gov/files/drugs/published/Best-Practices-for-Conducting-and-Reporting-Pharmacoepidemiologic-Safety-Studies-Using-Electronic-Healthcare-Data-Sets.pdf.

7.胥洋, 丁呈怡, 卓琳, 等. 《中国药物流行病学研究方法学指南（T/CPHARMA 002-2019）》团体标准制定过程[J]. 中华流行病学杂志, 2019, 40(10): 1186-1190. [Xu Y, Ding CY, Zhuo L. Developing process of Guide on Methodological Standards in Pharmacoepidemiology (T/CPHARMA 002-2019)[J]. Chinese Journal of Pharmacoepidemiology, 2019, 40(10): 1186-1190.] DOI: 10.3760/cma.j.issn.0254-6450.2019.10.003.

8.Meade MH, Michael M, Henzes J, et al. How to write an abstract[J]. Clin Spine Surg, 2024, 37(10): 504-505. DOI: 10.1097/BSD.0000000000001667.

9.Fried T, Foltz C, Lendner M, et al. How to write an effective introduction[J]. Clin Spine Surg, 2019, 32(3): 111-112. DOI: 10.1097/BSD.0000000000000714.

10.Cuschieri S. The STROBE guidelines[J]. Saudi J Anaesth, 2019, 13(Suppl 1): S31-S34. DOI: 10.4103/sja.SJA_543_18.

11.Ioannidis JPA, Gwinn M, Little J, et al. A road map for efficient and reliable human genome epidemiology[J]. Nature Genetics, 2006, 38(1): 3-5. DOI: 10.1038/ng0106-3.

12.Little J, Higgins JPT, Ioannidis JPA, et al. STrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the STROBE statement[J]. Genet Epidemiol, 2009, 33(7): 581-598. DOI: 10.1002/gepi.20410.

13.聂晓路, 彭晓霞. 使用常规收集卫生数据开展观察性研究的报告规范-RECORD规范[J]. 中国循证医学杂志, 2017, 17(4): 475-487. [Nie XL, Peng XX. The reporting of studies conducted using observational routinely-collected health data (RECORD) statement[J]. Chinese Journal of Evidence-Based Medicine, 2017, 17(4): 475-487.] DOI: 10.7507/1672-2531.201702009.

14.Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)[J]. BMJ, 2018, 363:k3532. DOI: 10.1136/bmj.k3532.

15.Tacconelli E, Cataldo MA, Paul M, et al. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship [J]. BMJ Open, 2016, 6(2): e010134. DOI: 10.1136/bmjopen-2015-010134.

16.Wang SV, Pottegård A, Crown W, et al. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR task force [J]. Pharmacoepidemiol Drug Saf, 2023, 32(1): 44-55. DOI: 10.1002/pds.5507.

17.Butcher NJ, Monsour A, Mew EJ, et al. Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension[J]. JAMA, 2022, 328(22): 2252-2264. DOI: 10.1001/jama.2022.21022.

18.Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials[J]. BMJ, 2025, 389: e081123. DOI: 10.1136/bmj-2024-081123.

19.Gagnier JJ, Boon H, Rochon P, et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement[J]. Ann Intern Med, 2006, 144(5): 364-367. DOI: 10.7326/0003-4819-144-5-200603070-00013.

20.Campbell MK, Piaggio G, Elbourne DR, et al. Consort 2010 statement: extension to cluster randomised trials[J]. BMJ, 2012, 345: e5661. DOI: 10.1136/bmj.e5661.

21.Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement[J]. JAMA, 2012, 308(24): 2594-2604. DOI: 10.1001/jama.2012.87802.

22.Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials[J]. BMJ, 2016, 355: i5239. DOI: 10.1136/bmj.i5239.

23.Cheng CW, Wu TX, Shang HC, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration[J]. Ann Intern Med, 2017, 167(2): 112-121. DOI: 10.7326/m16-2977.

24.Liu X, Cruz Rivera S, Moher D, et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension[J]. Lancet Digit Health, 2020, 2(10): e537-e548. DOI: 10.1016/s2589-7500(20)30218-1.

25.Kwakkenbos L, Imran M, Mccall SJ, et al. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration[J]. BMJ, 2021, 373: n857. DOI: 10.1136/bmj.n857.

26.Chan AW, Boutron I, Hopewell S, et al. SPIRIT 2025 statement: updated guideline for protocols of randomized trials[J]. Nat Med, 2025, 31(6): 1784-1792. DOI: 10.1038/s41591-025-03668-w.

27.Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials[J]. Ann Intern Med, 2013, 158(3): 200-207. DOI: 10.7326/0003-4819-158-3-201302050-00583.

28.Chan AW, Boutron I, Hopewell S, et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials[J]. BMJ, 2025, 389: e081477. DOI: 10.1136/bmj-2024-081477.

29.Dai L, Cheng CW, Tian R, et al. Standard protocol items for clinical trials with traditional Chinese medicine 2018: recommendations, explanation and elaboration (SPIRIT-TCM Extension 2018)[J]. Chin J Integr Med, 2019, 25(1): 71-79. DOI: 10.1007/s11655-018-2999-x.

30.Calvert M, King M, Mercieca-bebber R, et al. SPIRIT-PRO extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials[J]. BMJ Open, 2021, 11(6): e045105. DOI: 10.1136/bmjopen-2020- 045105.

31.Cruz Rivera S, Liu X, Chan AW, et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension[J]. Nat Med, 2020, 26(9): 1351-1363. DOI: 10.1038/s41591-020-1037-7.

32.Kahan BC, Hall SS, Beller EM, et al. Consensus statement for protocols of factorial randomized trials: extension of the SPIRIT 2013 statement[J]. JAMA Netw Open, 2023, 6(12): e2346121. DOI: 10.1001/jamanetworkopen.2023.46121.

33.Manyara AM, Davies P, Stewart D, et al. Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE[J]. BMJ Open, 2022, 12(10): e064304. DOI: 10.1136/bmjopen-2022-064304.

34.Espinasse A, Solovyeva O, Dimairo M, et al. SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol[J]. BMJ Open, 2023, 13(3): e068173. DOI: 10.1136/bmjopen-2022-068173.

35.Grech V, Eldawlatly AA. STROBE, CONSORT, PRISMA, MOOSE, STARD, SPIRIT, and other guidelines-overview and application[J]. Saudi J Anaesth, 2024, 18(1): 137-141. DOI: 10.4103/sja.sja_545_23.

36.Mcinnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and Meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement[J]. JAMA, 2018, 319(4): 388-396. DOI: 10.1001/jama.2017.19163.

37.Welch V, Petticrew M, Tugwell P, et al. PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity[J]. PLoS Med, 2012, 9(10): e1001333. DOI: 10.1371/journal.pmed.1001333.

38.Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and Meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation[J]. BMJ, 2015, 350: g7647. DOI: 10.1136/bmj.g7647.

39.Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network Meta-analyses of health care interventions: checklist and explanations[J]. Ann Intern Med, 2015, 162(11): 777-784. DOI: 10.7326/m14-2385.

40.Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation[J]. Ann Intern Med, 2018, 169(7): 467-473. DOI: 10.7326/m18-0850.

41.Zhang X, Tan R, Lam W C, et al. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) extension for Chinese herbal medicines 2020 (PRISMA-CHM 2020) [J]. Am J Chin Med, 2020, 48(6): 1279-1313. DOI: 10.1142/s0192415x20500639.

42.Elsman EBM, Baba A, Offringa M. PRISMA-COSMIN 2024: new guidance aimed to enhance the reporting quality of systematic reviews of outcome measurement instruments[J]. Int J Nurs Stud, 2024, 160: 104880. DOI: 10.1016/j.ijnurstu.2024.104880.

43.Akl EA, Khabsa J, Iannizzi C, et al. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation[J]. BMJ, 2024, 387: e079183. DOI: 10.1136/bmj-2024-079183.

44.European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP) Module VIII-post-authorisation safety studies (Rev 3)[S/OL]. (2017-10-13) [2025-07-18]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf.

45.European Medicines Agency. Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies[S/OL]. (2013-07-30) [2025-07-18]. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-and-content-final-study-report-non-interventional-post-authorisation-safety-studies_en.pdf.

46.Lee H, Cashin AG, Lamb SE, et al. A guideline for reporting mediation analyses of randomized trials and observational studies: the AGReMA statement[J]. JAMA, 2021, 326(11): 1045-1056. DOI: 10.1001/jama.2021.14075.

47.Helmy R, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP medication adherence reporting guidelines (EMERGE): a reactive-Delphi study protocol[J]. BMJ Open, 2017, 7(2): e013496. DOI: 10.1136/bmjopen-2016-013496.

48.邢唯杰, 朱政, 胡雁, 等. 实施性研究的报告规范(StaRI)解读[J]. 中国循证医学杂志, 2019, 19(1): 97-101. [Xing WJ, Zhu Z, Hu Y, et al. Interpretation of standards for reporting implementation studies (StaRI)[J]. Chinese Journal of Evidence-Based Medicine, 2019, 19(1): 97-101.] DOI: 10.7507/1672-2531.201808102.

49.Chaplin M, Kirkham JJ, Dwan K, et al. Strengthening the reporting of pharmacogenetic studies: development of the STROPS guideline[J]. PLoS Med, 2020, 17(9): e1003344. DOI: 10.1371/journal.pmed.1003344.

50.Smiley A, Villarreal-zegarra D, Reategui-rivera CM, et al. Methodological and reporting quality of machine learning studies on cancer diagnosis, treatment, and prognosis[J]. Front Oncol, 2025, 15: 1555247. DOI: 10.3389/fonc.2025.1555247.

51.El Emam K, Leung TI, Malin B, et al. Consolidated reporting guidelines for prognostic and diagnostic machine learning models (CREMLS)[J]. J Med Internet Res, 2024, 26: e52508. DOI: 10.2196/52508.

52.Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement[J]. BMJ, 2015, 350: g7594. DOI: 10.1136/bmj.g7594.

53.Collins GS, Dhiman P, Andaur Navarro CL, et al. Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence[J]. BMJ Open, 2021, 11(7): e048008. DOI: 10.1136/bmjopen-2020-048008.

54.Gallifant J, Afshar M, Ameen S, et al. The TRIPOD-LLM reporting guideline for studies using large language models[J]. Nat Med, 2025, 31(1): 60-69. DOI: 10.1038/s41591-024-03425-5.

55.Thiese MS. Observational and interventional study design types: an overview[J]. Biochem Med (Zagreb), 2014, 24(2): 199-210. DOI: 10.11613/bm.2014.022.

56.Snyder N, Foltz C, Lendner M, et al. How to write an effective results section[J]. Clin Spine Surg, 2019, 32(7): 295-296. DOI: 10.1097/bsd.0000000000000845.

57.Gatto NM, Wang SV, Murk W, et al. Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting[J]. Pharmacoepidemiol Drug Saf, 2022, 31(11): 1140-1152. DOI: 10.1002/pds.5529.

58.Phillips R, Cro S, Wheeler G, et al. Visualising harms in publications of randomised controlled trials: consensus and recommendations[J]. BMJ, 2022, 377: e068983. DOI: 10.1136/bmj-2021-068983.

59.卢存存, 陈子佳, 乔萌, 等. 随机对照试验报告中危害结局数据可视化的共识与推荐解读[J]. 中国循证医学杂志, 2023, 23(09): 1110-1116. [Lu CC, Chen ZJ, Qiao M, et al. Interpretation of consensus and recommendations of harms visualization in reports of randomized controlled trials[J]. Chinese Journal of Evidence-Based Medicine, 2023, 23(9): 1110-1116.] DOI: 10.7507/1672-2531.202305017.

60.In J, Lee S. Statistical data presentation[J]. Korean J Anesthesiol, 2017, 70(3): 267. DOI: 10.4097/kjae.2017.70.3.267.

61.Muka T, Glisic M, Milic J, et al. A 24-step guide on how to design, conduct, and successfully publish a systematic review and Meta-analysis in medical research[J]. Eur J Epidemiol, 2020, 35(1): 49-60. DOI: 10.1007/s10654-019-00576-5.

62.Makar G, Foltz C, Lendner M, et al. How to write effective discussion and conclusion sections[J]. Clin Spine Surg, 2018, 31(8): 345-346. DOI: 10.1097/bsd.0000000000000687.

63.Zhang X, Chen L, Bracco OL, et al. Regulator-requested non-interventional postauthorization safety and effectiveness studies for oncology drugs: a systematic review[J]. Clin Pharmacol Ther, 2022, 111(1): 155-167. DOI: 10.1002/cpt.2450.

64.Zhou W, Xu Z, Liu S, et al. Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022[J]. BMC Cancer, 2024, 24(1): 898. DOI: 10.1186/s12885-024-12652-5.

65.Marilly E, Cottin J, Cabrera N, et al. SGLT2 inhibitors in type 2 diabetes: a systematic review and Meta-analysis of cardiovascular outcome trials balancing their risks and benefits[J]. Diabetologia, 2022, 65(12): 2000-2010. DOI: 10.1007/s00125-022-05773-8.

Popular papers
Last 6 months